WORCESTER, MA - May 24, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT) announced today that Dr. Douglas Powell, Director of Immunobiology at its wholly-owned Antigen Express subsidiary, has presented Antigen's vaccine development strategy at an international conference in London, UK. The international meeting, "Developing New Anti-Infective Agents - Challenges and Opportunities" (www.anti-infectives-forum.com), is being held May 24th and 25th and brings together leading individuals from academia, industry, and regulatory agencies.
The focus of Dr. Powell's presentation was the immunogenicity of proprietary peptide vaccines being developed by Antigen Express, both when used alone and in combination with other types of vaccines. The Company is currently conducting a Phase II clinical trial of one of its peptides in breast cancer patients and a Phase I trial in volunteers of other peptides for the potentially pandemic H5N1 avian influenza. In both of these disease areas, cancer and avian influenza, novel forms of immunotherapy and vaccine are clearly needed.
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMistT device. The Company's flagship product, oral insulin (Generex Oral-lynT), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core p latform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be reg arded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
# # #
For more information, please contact:
Shayne Gilliatt of Generex
800-391-6755 or 416-364-2551
Andrew Hellman of CEOcast, Inc.